Everything you care about in one place
Follow feeds: blogs, news, RSS and more. An effortless way to read and digest content of your choice.
Get Feedernews.sanofi.us
Press Room (Product News)
Get the latest updates from Press Room (Product News) directly as they happen.
Follow now 37 followers
Latest posts
Last updated over 3 years ago
Second Dupixent® (dupilumab) Phase 3 eosinophilic esophagitis trial to demonstrate significant disease improvements, underscoring role of type 2 inflammation in this complex disease
over 3 years ago
Dupixent 300 mg weekly significantly improved the ability to swallow and reduced...
Dupixent® (dupilumab) is the first biologic to significantly reduce itch and skin lesions in Phase 3 trial for prurigo nodularis, demonstrating the role of type 2 inflammation in this disease
over 3 years ago
Pivotal trial met primary and all key secondary endpoints
FDA expands approval of Dupixent® (dupilumab) to include children aged 6 to 11 years with moderate-to-severe asthma
over 3 years ago
Dupixent is the only biologic medicine to improve lung function in children...
Dupixent® (dupilumab) pivotal trial meets all primary and secondary endpoints becoming first biologic medicine to significantly reduce signs and symptoms of moderate-to-severe atopic dermatitis in children as young as 6 months
over 3 years ago
Dupixent rapidly improved symptoms after first dose, improving itch in one week...
FDA approves Nexviazyme® (avalglucosidase alfa-ngpt), an important new treatment option for late-onset Pompe disease
almost 4 years ago
Approval is based on positive Phase 3 data demonstrating improvements in key...
New Soliqua 100/33 data shows improved blood sugar control without weight gain versus premixed insulin
almost 4 years ago
* Study also shows more people on Soliqua 100/33 had improved blood...
Nirsevimab shows positive topline results in RSV Phase 2/3 MEDLEY trial
almost 4 years ago
- Respiratory syncytial virus (RSV) is the leading cause of hospitalization in...
Newly licensed US manufacturing facility to increase availability of Fluzone® High-Dose Quadrivalent (influenza vaccine)
almost 4 years ago
* $425 million investment in Sanofi's Swiftwater, PA facility expands production of...
Sanofi and Merck's first and only six-in-one pediatric combination vaccine now available in the United States
almost 4 years ago
* This combination vaccine may simplify execution and reduce shots needed to...